Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

Rhea-AI Summary

Kymera Therapeutics, a biopharmaceutical company focused on targeted protein degradation, announced that CEO Nello Mainolfi will present at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 5:00 p.m. ET. The presentation can be accessed via a live webcast on the company's website, with an archived version available for 90 days. Kymera's focus includes developing therapeutics that target difficult disease-causing proteins, specifically through its Pegasus platform, addressing immune-inflammatory diseases and tumors.

WATERTOWN, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the virtual Morgan Stanley 18th Annual Global Healthcare Conference at 5:00 p.m. ET on Wednesday, Sept. 16, 2020.

A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. An archived webcast recording of the presentation will be available on the website for approximately 90 days.

About Kymera Therapeutics

Kymera Therapeutics is a biopharmaceutical company focused on a transformative new approach to address previously intractable disease targets. Kymera is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera’s Pegasus targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. Kymera’s initial programs target IRAK4, IRAKIMiD and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies and solid tumors. For more information, visit www.kymeratx.com.

Contact:

Investors@kymeratx.com
Bruce Jacobs
Chief Financial Officer
+1 857.285.5300

Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com
+1 339.970.2843

media@kymeratx.com

Lissette L. Steele
Verge Scientific Communications for Kymera Therapeutics
lsteele@vergescientific.com
+1 202.930.4762

FAQ

What time will Kymera Therapeutics present at the Morgan Stanley Conference on September 16, 2020?

Kymera Therapeutics will present at 5:00 p.m. ET on September 16, 2020.

Where can I watch the Kymera Therapeutics presentation from the Morgan Stanley Conference?

The presentation can be watched live on the 'Events and Presentations' section of Kymera's website.

What is the focus of Kymera Therapeutics in drug development?

Kymera Therapeutics focuses on targeted protein degradation to develop therapeutics for immune-inflammatory diseases and tumors.

What are the initial programs Kymera Therapeutics is targeting?

Kymera's initial programs target IRAK4, IRAKIMiD, and STAT3 within IL-1R/TLR or JAK/STAT pathways.

How does Kymera Therapeutics approach disease-causing proteins?

Kymera harnesses the body’s protein recycling system to selectively degrade disease-causing proteins.